Apimeds Pharmaceuticals Us's Comment on Sales, Marketing and Customers
Apitox, developed by Apimeds Korea, has been approved and marketed in South Korea for the treatment of osteoarthritis (OA) since 2003, with over 3,000 patients treated and no serious adverse events reported. Apimeds Korea intends to obtain FDA approval for Apitox in the United States to address inflammation and pain management symptoms associated with knee OA, with plans to expand its use to multiple sclerosis (MS) and the broader autoimmune market through a strategic marketing partner. The company plans to apply for temporary generic reimbursement codes from the Centers for Medicare and Medicaid Services (CMS) prior to Biologics License Application (BLA) approval. Apimeds will engage third-party contractors to support reimbursement, coding, and policy development, including coding assessment, medical coverage policy analysis, Medicare local coverage analysis, and Medicaid and commercial coverage analysis for major payers and state Medicaid agencies.
Apimeds Pharmaceuticals Us’s Comment on Sales, Marketing and Customers
Apitox, developed by Apimeds Korea, has been approved and marketed in South Korea for the treatment of osteoarthritis (OA) since 2003, with over 3,000 patients treated and no serious adverse events reported. Apimeds Korea intends to obtain FDA approval for Apitox in the United States to address inflammation and pain management symptoms associated with knee OA, with plans to expand its use to multiple sclerosis (MS) and the broader autoimmune market through a strategic marketing partner. The company plans to apply for temporary generic reimbursement codes from the Centers for Medicare and Medicaid Services (CMS) prior to Biologics License Application (BLA) approval. Apimeds will engage third-party contractors to support reimbursement, coding, and policy development, including coding assessment, medical coverage policy analysis, Medicare local coverage analysis, and Medicaid and commercial coverage analysis for major payers and state Medicaid agencies.
Sources:
Apimeds Pharmaceuticals US, Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Apimeds Pharmaceuticals US, Inc.’s corporate clients.
For your research, we’ve provided 9 tables on Apimeds Pharmaceuticals US, Inc. corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
